Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 1939052, 17 pages
http://dx.doi.org/10.1155/2016/1939052
Research Article

Neuroprotective Effects of the Herbal Formula B401 in Both Cell and Mouse Models of Alzheimer’s Disease

1Department of Life Sciences, National Taiwan Normal University, Taipei City, Taiwan
2Department of Pathological Inspection, Saint Paul’s Hospital, Taoyuan City, Taiwan
3Brion Research Institute of Taiwan, New Taipei City, Taiwan

Received 6 May 2016; Accepted 26 July 2016

Academic Editor: Jian-Li Gao

Copyright © 2016 Chih-Hsiang Hsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Braak and E. Braak, “Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections,” Brain Pathology, vol. 1, no. 3, pp. 213–216, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Braak and E. Braak, “Neuropathological stageing of Alzheimer-related changes,” Acta Neuropathologica, vol. 82, no. 4, pp. 239–259, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Nair, M. Traini, I. W. Dawes, and G. G. Perrone, “Genome-wide analysis of Saccharomyces cerevisiae identifies cellular processes affecting intracellular aggregation of Alzheimer's amyloid-β42: importance of lipid homeostasis,” Molecular Biology of the Cell, vol. 25, no. 15, pp. 2235–2249, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Zempel, J. Luedtke, Y. Kumar et al., “Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin,” The EMBO Journal, vol. 32, no. 22, pp. 2920–2937, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. S. Lee, H. Y. Kim, H. M. Youn, J. H. Seo, Y. Kim, and K. J. Shin, “2-Phenylbenzofuran derivatives alleviate mitochondrial damage via the inhibition of β-amyloid aggregation,” Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 21, pp. 5882–5886, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Capetillo-Zarate, L. Gracia, D. Tampellini, and G. K. Gouras, “Intraneuronal Aβ accumulation, amyloid plaques, and synapse pathology in Alzheimer's disease,” Neuro-Degenerative Diseases, vol. 10, no. 1–4, pp. 56–59, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Kontsekova, N. Zilka, B. Kovacech, R. Skrabana, and M. Novak, “Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease,” Alzheimer's Research & Therapy, vol. 6, no. 4, article 45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Stoppelkamp, H. S. Bell, J. Palacios-Filardo, D. A. Shewan, G. Riedel, and B. Platt, “In vitro modelling of Alzheimer's disease: degeneration and cell death induced by viral delivery of amyloid and tau,” Experimental Neurology, vol. 229, no. 2, pp. 226–237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. G. Henriques, J. M. Oliveira, L. P. Carvalho, and O. A. B. da Cruz e Silva, “Aβ influences cytoskeletal signaling cascades with consequences to Alzheimer’s disease,” Molecular Neurobiology, vol. 52, no. 3, pp. 1391–1407, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. M. Oliveira, A. G. Henriques, F. Martins, S. Rebelo, and O. A. B. da Cruz E Silva, “Amyloid-β modulates both AβPP and Tau phosphorylation,” Journal of Alzheimer's Disease, vol. 45, no. 2, pp. 495–507, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Lewczuk, B. Mroczko, A. Fagan, and J. Kornhuber, “Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective,” Advances in Medical Sciences, vol. 60, no. 1, pp. 76–82, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Madhusoodanan and M. B. Ting, “Pharmacological management of behavioral symptoms associated with dementia,” World Journal of Psychiatry, vol. 4, pp. 72–79, 2014. View at Google Scholar
  13. M. Farokhnia, M. Shafiee Sabet, N. Iranpour et al., “Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial,” Human Psychopharmacology, vol. 29, no. 4, pp. 351–359, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Tu, S.-I. Okamoto, S. A. Lipton, and H. Xu, “Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease,” Molecular Neurodegeneration, vol. 9, pp. 48–60, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. A. El-Malah, E. M. Gedawy, A. E. Kassab, and R. M. A. Salam, “Novel tacrine analogs as potential cholinesterase inhibitors in Alzheimer's disease,” Archiv der Pharmazie, vol. 347, no. 2, pp. 96–103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Murray, M. Faraoni, M. Castro, N. Alza, and V. Cavallaro, “Natural AChE inhibitors from plants and their contribution to alzheimer’s disease therapy,” Current Neuropharmacology, vol. 11, no. 4, pp. 388–413, 2013. View at Publisher · View at Google Scholar
  17. S. Moghul and D. Wilkinson, “Use of acetylcholinesterase inhibitors in Alzheimer's disease,” Expert Review of Neurotherapeutics, vol. 1, no. 1, pp. 61–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. R.-W. Han, R.-S. Zhang, M. Chang et al., “Reversal of scopolamine-induced spatial and recognition memory deficits in mice by novel multifunctional dimers bis-cognitins,” Brain Research, vol. 1470, pp. 59–68, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Murray, M. Faraoni, M. Castro, N. Alza, and V. Cavallaro, “Natural AChE inhibitors from plants and their contribution to Alzheimer’s disease therapy,” Current Neuropharmacology, vol. 11, no. 4, pp. 388–413, 2013. View at Publisher · View at Google Scholar
  20. S.-E. Wang, C.-L. Lin, C.-H. Hsu, S.-J. Sheu, C.-T. Chien, and C.-H. Wu, “Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease,” Drug Design, Development and Therapy, vol. 9, pp. 887–900, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. S.-E. Wang, C.-L. Lin, C.-H. Hsu, S.-J. Sheu, and C.-H. Wu, “Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice,” Clinical Interventions in Aging, vol. 10, pp. 1825–1837, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Peng, J. Wuu, E. J. Mufson, and M. Fahnestock, “Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease,” Journal of Neurochemistry, vol. 93, no. 6, pp. 1412–1421, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. R. M. D. Holsinger, J. Schnarr, P. Henry, V. T. Castelo, and M. Fahnestock, “Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease,” Molecular Brain Research, vol. 76, no. 2, pp. 347–354, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Connor, D. Young, Q. Yan, R. L. M. Faull, B. Synek, and M. Dragunow, “Brain-derived neurotrophic factor is reduced in Alzheimer's disease,” Molecular Brain Research, vol. 49, no. 1-2, pp. 71–81, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. H. S. Phillips, J. M. Hains, M. Armanini, G. R. Laramee, S. A. Johnson, and J. W. Winslow, “BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease,” Neuron, vol. 7, no. 5, pp. 695–702, 1991. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Oddo, A. Caccamo, J. D. Shepherd et al., “Triple-transgenic model of Alzheimer's Disease with plaques and tangles: intracellular Aβ and synaptic dysfunction,” Neuron, vol. 39, no. 3, pp. 409–421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. Mastrangelo and W. J. Bowers, “Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice,” BMC Neuroscience, vol. 9, article 81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. H.-J. Huang, W.-L. Chen, R.-H. Hsieh, and H. M. Hsieh-Li, “Multifunctional effects of mangosteen pericarp on cognition in C57BL/6J and triple transgenic alzheimer's mice,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 813672, 18 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. J. L. Jankowsky, D. J. Fadale, J. Anderson et al., “Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase,” Human Molecular Genetics, vol. 13, no. 2, pp. 159–170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Sterniczuk, M. C. Antle, F. M. Laferla, and R. H. Dyck, “Characterization of the 3xTg-AD mouse model of Alzheimer's disease—part 2: behavioral and cognitive changes,” Brain Research, vol. 1348, pp. 149–155, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S.-H. Kwon, H.-K. Lee, J.-A. Kim et al., “Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice,” European Journal of Pharmacology, vol. 649, no. 1–3, pp. 210–217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Barbero-Camps, A. Fernández, L. Martínez, J. C. Fernández-Checa, and A. Colell, “APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease,” Human Molecular Genetics, vol. 22, no. 17, pp. 3460–3476, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. S. F. Kazim, J. Blanchard, C.-L. Dai et al., “Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease,” Neurobiology of Disease, vol. 71, pp. 110–130, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Ruiz de Almodovar, D. Lambrechts, M. Mazzone, and P. Carmeliet, “Role and therapeutic potential of VEGF in the nervous system,” Physiological Reviews, vol. 89, no. 2, pp. 607–648, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Z. Chong, F. Li, and K. Maiese, “Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease,” Progress in Neurobiology, vol. 75, no. 3, pp. 207–246, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. L. L. Dos Santos-Neto, M. A. de Vilhena Toledo, P. Medeiros-Souza, and G. A. de Souza, “The use of herbal medicine in Alzheimer's disease—a systematic review,” Evidence-Based Complementary and Alternative Medicine, vol. 3, no. 4, pp. 441–445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. S. V. More, H. Kumar, S. M. Kang, S.-Y. Song, K. Lee, and D.-K. Choi, “Advances in neuroprotective ingredients of medicinal herbs by using cellular and animal models of Parkinson's disease,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 957875, 15 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Satoh, T. Takahashi, K. Iwasaki et al., “Traditional Chinese medicine on four patients with Huntington's disease,” Movement Disorders, vol. 24, no. 3, pp. 453–455, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. X.-C. Chen, Y.-G. Zhu, L.-A. Zhu et al., “Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress,” European Journal of Pharmacology, vol. 473, no. 1, pp. 1–7, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Yu, S. Li, H. Yang, F. Lee, J.-T. Wu, and M. G. Qian, “A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery,” Rapid Communications in Mass Spectrometry, vol. 19, no. 2, pp. 250–254, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. D. J. Selkoe, “Alzheimer's disease is a synaptic failure,” Science, vol. 298, no. 5594, pp. 789–791, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. S. W. Scheff, D. A. Price, F. A. Schmitt, and E. J. Mufson, “Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment,” Neurobiology of Aging, vol. 27, no. 10, pp. 1372–1384, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. N. A. Evans, L. Facci, D. E. Owen et al., “Aβ1–42 reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: a quantitative analysis,” Journal of Neuroscience Methods, vol. 175, no. 1, pp. 96–103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Religa, R. Cao, D. Religa et al., “VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival,” Scientific Reports, vol. 3, article 2053, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. W. R. Markesbery, “Oxidative stress hypothesis in Alzheimer's disease,” Free Radical Biology & Medicine, vol. 23, no. 1, pp. 134–147, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. B. Frank and S. Gupta, “A review of antioxidants and Alzheimer's disease,” Annals of Clinical Psychiatry, vol. 17, no. 4, pp. 269–286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. J. V. Smith and Y. Luo, “Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761,” Journal of Alzheimer's Disease, vol. 5, no. 4, pp. 287–300, 2003. View at Google Scholar · View at Scopus